N/A N=76 TXA Study in Major Oncologic Surgery
Tranexamic Acid · Cancer · Major Surgery
Primary: Number of Participants Who Required Transfusion — 8; 5 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=1,409 Post-Discharge Smoking Cessation Strategies: Helping HAND 4
Smoking Cessation
Primary: Tobacco Abstinence, Biochemically Confirmed — 110; 96 Participants — p=.19
Phase 4 N=40 Tolvaptan For Worsening Outpatient Heart Failure: Role of Copeptin In Identifying Responders
Congestive Heart Failure
Primary: Change in Body Weight at 48 Hours — -3.3; -0.8 pounds — p=0.094
N/A N=41 Acupuncture for Low-Dose Opioid for TKA Replacement
Knee Osteoarthritis · Pain, Postoperative · Acupuncture
Primary: Low-dose Opioid Regimen Adherence — 26 participants
Phase 3 N=1,502 Safety and Efficacy of an Antibiotic Implant in Cardiac Surgical Subjects at Higher Risk for Sternal Wound Infection
Cardiac Surgery · Sternal Wound Infection
Primary: Number of Participants With Surgical Wound Infections From Surgery Through Post-operative Day 90 — 63; 65 Participants
N/A N=8 Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study
Non-Alcoholic Fatty Liver Disease
Primary: Participants With Normalized Liver Enzyme Levels — 0; 0 Participants
Phase 2 N=201 Determination of the Sensitivity and Specificity of Prick Test Betula Verrucosa
Immune System Diseases
Primary: Sensitivity for 100 HEP/mL — 75; 0 positive reaction
Phase 4 N=662 Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS)
Multiple Sclerosis (MS)
Primary: Percentage of Participants Using Wheelchair or Being Bedridden Assessed by Expanded Disability Status Scale (EDSS) Score 7.0 or Higher — 8.2 percentage of participant
N/A N=378 Efficacy and Safety of IBS Digital Behavioral Treatment
Irritable Bowel Syndrome
Primary: Abdominal Pain Intensity Responder — 55; 49 Participants — p=0.5352
Phase 3 N=658 A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)
Wet Macular Degeneration
Primary: Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 40, 44, and 48 — 6.6; 6.6 ETDRS Letters
Phase 2 N=77 Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms
Peripheral T Cell Lymphoma · PTCL · Extranodal NK/T-cell Lymphoma
Primary: Overall Response Rate (ORR) — 31.8; 20.5; 45.5 Percentage of participants
N/A N=71 A Safety and Feasibility Study of the FARAPULSE Endocardial Ablation System to Treat Paroxysmal Atrial Fibrillation
Paroxysmal Atrial Fibrillation
Primary: The Primary Safety Endpoint for This Study is the Composite Safety Endpoint (CSE) Defined as the Proportion of Patients With Early-onset and Late-onset Serious Adverse…
Phase 2 N=89 Open, Randomized Phase II Trial to Investigate the Efficacy and Safety of the PLK-1 Inhibitor BI 2536 in Patients With Advanced, Unresectable Pancreatic Cancer
Pancreatic Neoplasms
Primary: Best Objective Response Evaluated According to the RECIST Criteria by Independent Review — 0; 0; 1; 1 Participants — p=0.7021
N/A N=10 PEFCATII Expanded Safety and Feasibility Study of the FARAPULSE Endocardial Multi Ablation System to Treat Paroxysmal Atrial Fibrillation
Paroxysmal Atrial Fibrillation
Primary: Safety: Number of Participants With Prespecified Primary Safety Events Within 30 Days of Index Procedure. — 0 Participants
Phase 3 N=671 A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)
Wet Macular Degeneration
Primary: Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 40, 44, and 48 — 5.8; 5.1 ETDRS Letters